tag financial-results 
PharmaShots
FEBRUARY 17, 2023
Iveric Bio Reports the US FDA Acceptance of NDA and Granted Priority Review of Avacincaptad Pegol for Geographic Atrophy Date: Feb 17, 2023 | Tags: Iveric Bio, Avacincaptad Pegol, Geographic Atrophy, Regulatory, US, FDA, NDA, Priority Review ALX Oncology Reports the First Patient Dosing of Evorpacept in the P-I Study (ASPEN-07) for the Treatment of (..)
pharmaphorum
AUGUST 17, 2020
The financial world, like the pharmaceutical industry, must operate within a tightly-defined regulatory environment, and in doing so has proved adept at connecting with its customers. Interactions between sales reps and HCPs has shifted to more digital forms of communication as a result of the lack of face-to-face interaction.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
RX Note
MAY 1, 2023
Introduction The internet is full of financial gurus and self-proclaimed experts who claim to have the secrets and strategies to help you achieve financial freedom and live the life you want. However, is it really that easy to attain financial stability, especially at young age? As a result, we will never earn too much money.
pharmaphorum
JANUARY 24, 2022
IBM said the sell-off is tagged as “a clear next step” as it focuses on its platform-based hybrid cloud and artificial intelligence strategy, but it’s no secret that Watson Health has failed to live up to its early promise.
Pharmaceutical Technology
FEBRUARY 10, 2023
This is not the first treatment to come with a high price tag. An overwhelming 79% of known RSAs are finance-based, ranging in complexity from simple discount schemes to more complex risk-based financial arrangements. million, according to GlobalData’s Price Intelligence (POLI), making it the most expensive drug in the world.
pharmaphorum
NOVEMBER 24, 2022
Johnson & Johnson’s Spravato therapy for treatment-resistant depression (TRD) hasn’t made the impact the company hoped for in the market, and it is looking to new clinical results to accelerate its take-up.
pharmaphorum
JUNE 2, 2022
In 1983, the US Congress passed the Orphan Drug Act to encourage more pharmaceutical companies to engage in R&D to develop treatments for rare diseases through the offering of financial incentives. The broader movement across the industry is towards managing the financial cost of treatments. Raising questions.
Expert insights. Personalized for you.
40 
Let's personalize your content